MA47113A - Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation - Google Patents

Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation

Info

Publication number: MA47113A
Authority: MA; Morocco
Prior art keywords: neuropiline; methods; antigen binding; binding proteins; proteins
Prior art date: 2016-12-23

Application number

MA047113A

Other languages

English (en)

Inventor

Heather Brodkin

Daniel Hicklin

Nels P Nielson

Jose-Andres Salmeron-Garcia

Cynthia Seidel-Dugan

William Winston

Original Assignee

Potenza Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-23

Filing date

2017-12-21

Publication date

2019-10-30

2017-12-21 Application filed by Potenza Therapeutics Inc filed Critical Potenza Therapeutics Inc

2019-10-30 Publication of MA47113A publication Critical patent/MA47113A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Epoxy Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

MA047113A 2016-12-23 2017-12-21 Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation MA47113A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662438733P	2016-12-23	2016-12-23

Publications (1)

Publication Number	Publication Date
MA47113A true MA47113A (fr)	2019-10-30

Family

ID=61025050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047113A MA47113A (fr)	2016-12-23	2017-12-21	Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation

Country Status (22)

Country	Link
US (3)	US10227413B2 (fr)
EP (1)	EP3558365B1 (fr)
JP (1)	JP2020511947A (fr)
KR (1)	KR20190099254A (fr)
CN (1)	CN110167590A (fr)
AR (1)	AR110659A1 (fr)
AU (1)	AU2017379062A1 (fr)
BR (1)	BR112019012796A2 (fr)
CA (1)	CA3046313A1 (fr)
CO (1)	CO2019007846A2 (fr)
EA (1)	EA201991546A1 (fr)
ES (1)	ES2963746T3 (fr)
IL (1)	IL267097A (fr)
JO (1)	JOP20190134A1 (fr)
MA (1)	MA47113A (fr)
MX (1)	MX2019007554A (fr)
PH (1)	PH12019501405A1 (fr)
SA (1)	SA519402159B1 (fr)
SG (1)	SG10201913855TA (fr)
TW (1)	TWI797100B (fr)
WO (1)	WO2018119171A1 (fr)
ZA (1)	ZA202003695B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20190134A1 (ar)	2016-12-23	2019-06-02	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
SG11201907299XA (en)	2017-02-08	2019-09-27	Dragonfly Therapeutics Inc	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (es)	2017-02-20	2023-11-28	Dragonfly Therapeutics Inc	Proteínas que se unen a HER2, NKG2D Y CD16
WO2019157366A1 (fr)	2018-02-08	2019-08-15	Dragonfly Therapeutics, Inc.	Domaines variables d'anticorps ciblant le récepteur nkg2d
EA202091888A1 (ru) *	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
US20220023342A1 (en) *	2018-11-30	2022-01-27	Institut Gustave Roussy	Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020141199A1 (fr) *	2019-01-03	2020-07-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et compositions pharmaceutiques pour améliorer les réponses immunitaires dépendantes des lymphocytes t cd8+ chez des sujets souffrant d'un cancer
TW202126685A (zh) *	2019-09-24	2021-07-16	德商百靈佳殷格翰國際股份有限公司	抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US20240018248A1 (en)	2020-12-02	2024-01-18	Vib Vzw	An ltbr agonist in combination therapy against cancer
US20240068004A1 (en) *	2022-08-15	2024-02-29	Mbrace Therapeutics, Inc.	Cell-free methods of producing antibodies to intracellular targets
US11965028B1 (en)	2023-01-19	2024-04-23	Theranovir	Neuropilin-1-peptide based antibody, highlighting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (fr)	1987-03-18	1988-09-22	Medical Research Council	Anticorps alteres
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
AU632065B2 (en)	1988-09-23	1992-12-17	Novartis Vaccines And Diagnostics, Inc.	Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
CA2103059C (fr)	1991-06-14	2005-03-22	Paul J. Carter	Methode de production d'anticorps humanises
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2129663C (fr)	1992-02-06	2005-07-05	James S. Huston	Proteine fixatrice biosynthetique pour marqueur du cancer
ATE244763T1 (de)	1992-02-11	2003-07-15	Cell Genesys Inc	Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5534615A (en)	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
DE69830315T2 (de)	1997-06-24	2006-02-02	Genentech Inc., San Francisco	Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
WO1999022764A1 (fr)	1997-10-31	1999-05-14	Genentech, Inc.	Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
JP2002510481A (ja)	1998-04-02	2002-04-09	ジェネンテック・インコーポレーテッド	抗体変異体及びその断片
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ATE458007T1 (de)	1998-04-20	2010-03-15	Glycart Biotechnology Ag	Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
ES2694002T3 (es)	1999-01-15	2018-12-17	Genentech, Inc.	Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
CA2704600C (fr)	1999-04-09	2016-10-25	Kyowa Hakko Kirin Co., Ltd.	Methode de production d'anticorps avec activite adcc accrue
JP4668498B2 (ja)	1999-10-19	2011-04-13	協和発酵キリン株式会社	ポリペプチドの製造方法
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
HU231090B1 (hu)	2000-10-06	2020-07-28	Kyowa Kirin Co., Ltd.	Antitest-kompozíciót termelő sejt
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT2316940E (pt)	2000-12-18	2013-10-16	Dyax Corp	Bibliotecas orientadas de pacotes genéticos
CA2838062C (fr)	2001-08-03	2015-12-22	Roche Glycart Ag	Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
HUP0600342A3 (en)	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
US20030215914A1 (en)	2001-12-10	2003-11-20	Erwin Houtzager	Structure for presenting desired peptide sequences
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
AU2003236020B2 (en)	2002-04-09	2009-03-19	Kyowa Hakko Kirin Co., Ltd.	Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
JPWO2003085118A1 (ja)	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物の製造方法
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JPWO2003084569A1 (ja)	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物含有医薬
WO2003084570A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
BR0309145A (pt)	2002-04-09	2005-02-01	Kyowa Hakko Kogyo Kk	Células das quais o genoma é modificado
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en)	2002-12-16	2011-01-11	Genentech Inc	Immunoglobulin variants and uses thereof
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
EP1705251A4 (fr)	2003-10-09	2009-10-28	Kyowa Hakko Kirin Co Ltd	Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de $g(a)1,6-fucosyltransferase
WO2005044859A2 (fr)	2003-11-05	2005-05-19	Glycart Biotechnology Ag	Molecules fixatrices d'antigenes presentant une affinite de fixation du recepteur de fc et une fonction effectrice accrues
JPWO2005053742A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
ES2403055T3 (es)	2004-04-13	2013-05-13	F. Hoffmann-La Roche Ag	Anticuerpos anti-P-selectina
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
WO2006034488A2 (fr)	2004-09-23	2006-03-30	Genentech, Inc.	Anticorps et conjugués produits avec de la cystéine
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
UA96139C2 (uk) *	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
AU2007353779B2 (en) *	2007-05-17	2013-11-07	Genentech, Inc.	Crystal structures of neuropilin fragments and neuropilin-antibody complexes
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en)	2007-09-14	2014-04-08	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
CN102666582B (zh)	2009-12-22	2016-03-30	弗·哈夫曼-拉罗切有限公司	序列依赖性聚集
CA2803792A1 (fr) *	2010-07-09	2012-01-12	Genentech, Inc.	Anticorps anti-neuropiline et leurs procedes d'utilisation
CN105734678B (zh)	2010-07-16	2019-11-05	阿迪马布有限责任公司	合成多核苷酸文库
JP2015533127A (ja) *	2012-10-08	2015-11-19	セントジュードチルドレンズリサーチホスピタルＳｔ．ＪｕｄｅＣｈｉｌｄｒｅｎ’ｓＲｅｓｅａｒｃｈＨｏｓｐｉｔａｌ	ニューロピリン１：セマフォリン軸を介した、制御性ｔ細胞の安定性および機能の制御に基づく療法
JOP20190134A1 (ar) *	2016-12-23	2019-06-02	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها

2017
- 2017-06-16 JO JOP/2019/0134A patent/JOP20190134A1/ar unknown
- 2017-12-21 BR BR112019012796A patent/BR112019012796A2/pt unknown
- 2017-12-21 EP EP17835532.7A patent/EP3558365B1/fr active Active
- 2017-12-21 MA MA047113A patent/MA47113A/fr unknown
- 2017-12-21 TW TW106145004A patent/TWI797100B/zh active
- 2017-12-21 CN CN201780079177.7A patent/CN110167590A/zh active Pending
- 2017-12-21 ES ES17835532T patent/ES2963746T3/es active Active
- 2017-12-21 CA CA3046313A patent/CA3046313A1/fr active Pending
- 2017-12-21 SG SG10201913855TA patent/SG10201913855TA/en unknown
- 2017-12-21 AU AU2017379062A patent/AU2017379062A1/en active Pending
- 2017-12-21 KR KR1020197020999A patent/KR20190099254A/ko not_active Application Discontinuation
- 2017-12-21 AR ARP170103623A patent/AR110659A1/es unknown
- 2017-12-21 JP JP2019533631A patent/JP2020511947A/ja active Pending
- 2017-12-21 MX MX2019007554A patent/MX2019007554A/es unknown
- 2017-12-21 WO PCT/US2017/067782 patent/WO2018119171A1/fr unknown
- 2017-12-21 EA EA201991546A patent/EA201991546A1/ru unknown
2018
- 2018-02-20 US US15/900,158 patent/US10227413B2/en active Active
2019
- 2019-01-03 US US16/239,234 patent/US11186644B2/en active Active
- 2019-06-05 IL IL267097A patent/IL267097A/en unknown
- 2019-06-19 PH PH12019501405A patent/PH12019501405A1/en unknown
- 2019-06-21 SA SA519402159A patent/SA519402159B1/ar unknown
- 2019-07-22 CO CONC2019/0007846A patent/CO2019007846A2/es unknown
2020
- 2020-06-19 ZA ZA2020/03695A patent/ZA202003695B/en unknown
2021
- 2021-10-25 US US17/509,351 patent/US20220098312A1/en active Pending

Also Published As

Publication number	Publication date
KR20190099254A (ko)	2019-08-26
EP3558365A1 (fr)	2019-10-30
AU2017379062A1 (en)	2019-06-20
US20220098312A1 (en)	2022-03-31
JOP20190134A1 (ar)	2019-06-02
PH12019501405A1 (en)	2019-10-28
EP3558365B1 (fr)	2023-09-13
TW201829466A (zh)	2018-08-16
CA3046313A1 (fr)	2018-06-28
SA519402159B1 (ar)	2023-12-14
US11186644B2 (en)	2021-11-30
US20180186886A1 (en)	2018-07-05
US10227413B2 (en)	2019-03-12
SG10201913855TA (en)	2020-03-30
CN110167590A (zh)	2019-08-23
AR110659A1 (es)	2019-04-17
ES2963746T3 (es)	2024-04-01
JP2020511947A (ja)	2020-04-23
ZA202003695B (en)	2023-01-25
CO2019007846A2 (es)	2019-08-20
BR112019012796A2 (pt)	2019-12-03
WO2018119171A1 (fr)	2018-06-28
TWI797100B (zh)	2023-04-01
EA201991546A1 (ru)	2020-01-17
US20190119389A1 (en)	2019-04-25
MX2019007554A (es)	2019-11-18
IL267097A (en)	2019-08-29

Publication	Publication Date	Title
MA47113A (fr)	2019-10-30	Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA43816A (fr)	2018-11-28	Protéines de liaison inductibles et méthodes d'utilisation
MA52273A (fr)	2021-04-28	Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA42446A (fr)	2018-05-23	Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA43576A (fr)	2018-11-14	Anticorps anti-lag3 et fragments de fixation à l'antigène
MA49512A (fr)	2020-05-06	Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA46917A (fr)	2019-09-25	Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
MA44524A (fr)	2019-02-06	Néoantigènes et leurs procédés d'utilisation
MA55347A (fr)	2022-01-26	Anticorps anti-lag3 et fragments de fixation à l'antigène
MA46566A (fr)	2019-08-28	Oxystérols et leurs procédés d'utilisation
MA42821A (fr)	2018-07-25	Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA42808A (fr)	2018-07-25	Anticorps de liaison à l'il-8 et leurs utilisations
MA45123A (fr)	2019-04-10	Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA53355A (fr)	2022-03-16	Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA50957A (fr)	2020-10-14	Anticorps anti-tigit et leurs méthodes d'utilisation
MA46529A (fr)	2019-08-21	Anticorps anti-lag-3 et leurs procédés d'utilisation
MA44885A (fr)	2019-03-13	Protéines de liaison bispécifiques et leurs utilisations
MA46565A (fr)	2019-08-28	Oxystérols et leurs procédés d'utilisation
MA49950A (fr)	2020-07-01	Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA43874A (fr)	2018-11-21	Constructions de liaison à l'antigène immunomodulateur multispécifique
MA50948A (fr)	2020-10-14	Anticorps et procédés d'utilisation de ceux-ci
MA44670A (fr)	2019-02-20	Protéines de liaison trispécifiques et/ou trivalentes
MA56165A (fr)	2022-04-20	Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA55097A (fr)	2022-01-05	Oxystérols et leurs procédés d'utilisation
MA42925A (fr)	2018-08-01	Anticorps anti-tigit et méthodes d'utilisation